Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Differentiel mål multiplekset rygmarvsstimulering (DETECT)

16. november 2026 opdateret af: Moens Maarten

Differentiel mål multiplekset rygmarvsstimulering: en multicenter kohorteundersøgelse

Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Anslået)

250

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Antwerp, Belgien
        • ZNA
      • Bruges, Belgien
        • AZ Sint-Jan Brugge-Oostende
      • Bruges, Belgien
        • AZ Sint-Lucas Brugge
      • Hasselt, Belgien
        • Jessa Ziekenhuis
      • Kortrijk, Belgien
        • AZ Groeninge
      • Leuven, Belgien
        • UZ Leuven
      • Lier, Belgien
        • Heilig Hart Ziekenhuis Lier
      • Liège, Belgien
        • Centre Hospitalier Régional (CHR) de la Citadelle
      • Mechelen, Belgien
        • AZ Sint-Maarten
      • Roeselare, Belgien
        • AZ Delta
      • Sint-Niklaas, Belgien
        • Vitaz
      • Turnhout, Belgien
        • AZ Turnhout
      • Wilrijk, Belgien
        • GZA
    • Brussels Capital
      • Jette, Brussels Capital, Belgien, 1090
        • Universitair Ziekenhuis Brussel

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.

Beskrivelse

Inclusion Criteria:

  • Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
  • Age > 18 years
  • Patient has been informed of the study procedures and has given written informed consent
  • Patient willing to comply with study protocol including attending the study visits

Exclusion Criteria:

  • Expected inability of the patient to receive or properly operate the spinal cord stimulation system
  • History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
  • Active malignancy
  • Addiction to drugs, alcohol (>5 units per day) and/or medication
  • Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
  • Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
  • Life expectancy < 1 year
  • Local infection or any other skin disorder at site of incision
  • Pregnancy
  • Other implanted active medical device

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Spinal cord stimulation

Patients will receive differential target multiplexed spinal cord stimulation

differential target multiplexed stimulation

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall pain intensity with Visual Analogue Scale (VAS)
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm)

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Intensitet af rygsmerter med Visual Analogue Scale (VAS)
Tidsramme: Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
Bensmerteintensitet med Visual Analogue Scale (VAS)
Tidsramme: Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
Klinisk holistisk responderstatus
Tidsramme: Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
Andel af vellykkede DTM-forsøg.
Tidsramme: Evalueret efter endelig SCS-implantation
Evalueret efter endelig SCS-implantation
Batteriforbrug
Tidsramme: Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
Udbredelse af tekniske problemer med hensyn til DTM SCS programmering
Tidsramme: Gennem hele studietiden
Gennem hele studietiden
DTM SCS-stimuleringsparametre
Tidsramme: Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
Pain medication use
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Open question regarding the dosage, frequency and type of pain medication

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Functional disability
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The functional disabilities will be assessed with the Oswestry Disability Index (ODI)

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Health related quality of life
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Patient global impression of change
Tidsramme: Evaluated at 1 month, 6 months and 12 months of DTM SCS.

Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC).

Evaluated at 1 month, 6 months and 12 months of DTM SCS.
Patients' individual competencies for self-management
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health.

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Work status
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Work status is evaluated with a self-designed questionnaire

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Pain catastrophizing
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Symptoms of central sensitisation.
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The Central Sensitization Inventory is used to measure symptoms of central sensitisation

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Anxiety and Depression.
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Healthcare utilisation.
Tidsramme: The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS

Postoperative healthcare expenditure will be investigated by self-reporting methods.

The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
Time spent in body postures
Tidsramme: The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months

Based on the AdaptiveStim technology, the time spent in body postures can be recorded.

The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
(Serious) adverse events
Tidsramme: Throughout study period

Systematically recording all adverse events

Throughout study period
Patient expectations concerning SCS
Tidsramme: Evaluated at baseline visit

Self-constructed open question to evaluate patient expectations about SCS

Evaluated at baseline visit

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. oktober 2021

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

9. september 2021

Først indsendt, der opfyldte QC-kriterier

26. september 2021

Først opslået (Faktiske)

5. oktober 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner